R&D News | pharmaphorum

News

SNIPR shoots down resistant E. coli in first human trial

SNIPR Biome has said its CRISPR therapeutic targeting a problem bacterial pathogen has shown proof-of-concept in a phase 1 trial, raising hopes of a new way to treat resis

News

Pfizer says haemophilia drug works, but safety will be key

Pfizer has reported that its anti-tissue factor pathway inhibitor marstacimab is effective at reducing bleed rates in patients with haemophilia A and B, working as well as

News

Elizabeth Holmes due to start prison sentence today

After years of legal wrangling, former Theranos chief executive Elizabeth Holmes is due to report later today at a federal prison, where she will start serving an 11-year

News

AZ chalks up another win for Imfinzi, Lynparza duo

AstraZeneca’s efforts to combine two of its top cancer drugs – Imfinzi and Lynparza – has been rewarded with positive results in an endometrial cancer study that could lea

News

Elon Musk’s Neuralink says FDA has cleared human trial

Neuralink has claimed in a tweet that it has finally received approval from the FDA to start a first-in-human clinical trial of its brain implant chip – but hasn’t indicat

News

Primary care a weak link in trials, says O’Shaughnessy

Primary care doctors in the UK are a “negligible” provider of commercial clinical trial activity and should be incentivised to give experimental therapies to patients.

SNIPR shoots down resistant E. coli in first human trial

Pfizer says haemophilia drug works, but safety will be key

Elizabeth Holmes due to start prison sentence today

AZ chalks up another win for Imfinzi, Lynparza duo

Elon Musk’s Neuralink says FDA has cleared human trial

Primary care a weak link in trials, says O’Shaughnessy

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks